Valuing Early-Stage Pharma Deals
This article was originally published in Start Up
Executive Summary
The emphasis within the pharmaceutical industry right now is on capital efficiency. That's led a number of firms - and their venture backers - to make what a few years ago would have been a heretical decision: eschewing drug development in favor of cutting platform-related deals. And how have such deals been valued? An analysis by START-UP of average deal value from 2007 to 2010 for platform, preclinical and Phase I assets shows pharmaceutical licensers are approaching alliances with a "budget" mindset, with average deal values declining across all stages of drug development.
You may also be interested in...
Ablexis' Pharmaceutical Consortium
Ablexis LLC's October 2010 consortium-based alliance with Pfizer Inc. and four other undisclosed "Top 15" drugmakers represents an important new variation in platform-technology deal-making.
The Allure Of High-Hanging Fruit: Why VCs and Biotech Execs See Value In Difficult Drug Targets
An agile and energetic cohort of biotech platform companies plans to capture Big Pharma's imagination--and its pocketbook--by going after intractable drug targets that have long eluded the industry, and they're doing it on a shoestring budget.
Ablexis' Pharmaceutical Consortium
Ablexis LLC's October 2010 consortium-based alliance with Pfizer Inc. and four other undisclosed "Top 15" drugmakers represents an important new variation in platform-technology deal-making.